Literature DB >> 8423463

In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.

M K Sharief1, R Hentges, M Ciardi, E J Thompson.   

Abstract

Interleukin (IL)-2 has well-recognized effects on cerebral endothelial cells and, therefore, may mediate disruption of the blood-brain barrier in patients with multiple sclerosis (MS). To evaluate the in vivo relationship of the IL-2 system to blood-brain barrier impairment in MS, levels of IL-2 and soluble IL-2 receptors (sIL-2R) in cerebrospinal fluid (CSF) and serum samples from 50 patients with active MS and 49 controls were correlated with values of the CSF to serum albumin ratio. Intrathecal levels of IL-2 and sIL-2R were significantly higher in MS compared with the control groups and correlated with albumin ratios in MS patients. Intrathecal levels of IL-2 and sIL-2R also correlated with the degree of barrier damage in these patients. It is suggested that intrathecal levels of IL-2 and sIL-2R are related to barrier impairment in MS and may be important in understanding some of the pathological changes of this condition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423463     DOI: 10.1007/bf00838446

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  41 in total

1.  Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis.

Authors:  K Adachi; T Kumamoto; S Araki
Journal:  Ann Neurol       Date:  1990-11       Impact factor: 10.422

2.  Interleukin-2 receptor levels indicating relapse in multiple sclerosis.

Authors:  K Adachi; T Kumamoto; S Araki
Journal:  Lancet       Date:  1989-03-11       Impact factor: 79.321

3.  The blood-brain barrier redefined.

Authors:  K Felgenhauer
Journal:  J Neurol       Date:  1986-08       Impact factor: 4.849

4.  Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values.

Authors:  G Tibbling; H Link; S Ohman
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

5.  Calculating confidence intervals for some non-parametric analyses.

Authors:  M J Campbell; M J Gardner
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

6.  Serum-CSF protein gradients, the blood-GSF barrier and the local immune response.

Authors:  G Schliep; K Felgenhauer
Journal:  J Neurol       Date:  1978-05-18       Impact factor: 4.849

7.  Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier.

Authors:  S C Saris; S A Rosenberg; R B Friedman; J T Rubin; D Barba; E H Oldfield
Journal:  J Neurosurg       Date:  1988-07       Impact factor: 5.115

8.  IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome.

Authors:  N K Damle; L V Doyle
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

9.  The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes.

Authors:  A S Bellamy; V L Calder; M Feldmann; A N Davison
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

10.  Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.

Authors:  D J Peace; M A Cheever
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  5 in total

1.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

2.  Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.

Authors:  C E Shaw; P R Dunbar; H A Macaulay; T J Neale
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

3.  Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis.

Authors:  M K Sharief; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-02       Impact factor: 10.154

4.  Differences in ABCA1 R219K Polymorphisms and Serum Indexes in Alzheimer and Parkinson Diseases in Northern China.

Authors:  Lagai Ya; Zuneng Lu
Journal:  Med Sci Monit       Date:  2017-09-25

Review 5.  Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics.

Authors:  Gerwyn Morris; Michael Maes
Journal:  BMC Med       Date:  2013-09-17       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.